Table 1.
Baseline characteristics.
| Target cancer site | All | Ovarian cancer | Breast cancer |
|---|---|---|---|
| N = 67 | N = 57 | N = 10 | |
| n (%) | n (%) | n (%) | |
| Age (years) mean (range, SD) | 55.9 (32–80, 10.5) | 57.7 (35–80, 10.0) | 46.1 (32–59, 8.3) |
| Gender | |||
| Male | 0 | 0 | 0 |
| Female | 67 (100%) | 57 (100%) | 10 (100%) |
| Mutated BRCA gene | |||
| 1 | 40 (60%) | 36 (63%) | 4 (40%) |
| 2 | 27 (40%) | 21 (37%) | 6 (60%) |
| Platinum-resistant disease | |||
| Yes | 49 (73%) | 49 (86%) | 0 |
| No | 8 (12%) | 8 (14%) | 0 |
| N/A (breast cancer patient) | 10 (15%) | 0 | 10 (100%) |
| Prior PARP treatment | |||
| Yes | 26 (39%) | 24 (42%) | 2 (20%) |
| No | 41 (61%) | 33 (58%) | 8 (80%) |
| No. of prior therapies mean (range, SD) | 4.7 (1–8, 2.2) | 4.2 (1–8, 2.3) | |
| ECOG performance status | |||
| 0 | 27 (40%) | 22 (39%) | 5 (50%) |
| 1 | 36 (54%) | 31 (54%) | 5 (50%) |
| 2 | 4 (6%) | 4 (7%) | 0 |
| Albumin levels, mean (range, SD) | 39.8 (28–49, 5.4) | 39.1 (28–49, 5.4) | 43.7 (39–49, 3.6) |
| <35 g/dl | 15 | 15 | 0 |
| ≥35 g/dl | 52 | 42 | 10 |
| Volume of disease | |||
| Visceral* | 34 (51%) | 26 (46%) | 8 (80%) |
| Bulky AP > 2 cm** | 24 (36%) | 24 (42%) | 0 |
| AP < 2 cm ± nodal | 4 (6%) | 4 (7%) | 0 |
| Nodal only | 5 (7%) | 3 (5%) | 2 (20%) |
| TPMT mean (range, SD) | 88.3 (43–160, 19.2) | 85.8 (43–135, 17.7) | 102.2 (84–160, 22.6) |
| <68 mU/L | 6 | 6 | 0 |
| ≥68 mU/L | 61 | 51 | 10 |
*Included patients both with and without bulky AP > 2 cm, AP < 2 cm and nodal disease.
**Included patients both with and without AP < 2 cm and nodal disease.